U.S. Organ-on-a-Chip Market To Reach $940.4 Million By 2033

U.S. Organ-on-a-Chip Market Growth & Trends

The U.S. organ-on-a-chip market size is anticipated to reach USD 940.4 million by 2033, growing at a CAGR of 33.14% from 2025 to 2033, according to a new report by Grand View Research, Inc. The U.S. organ-on-a-chip industry is witnessing substantial growth, fueled by rising demand from pharmaceutical, biotechnology, and academic research sectors for physiologically relevant in vitro models that more accurately mimic human biology. As drug discovery, toxicology testing, and personalized medicine evolve, organ-on-chip systems are critical tools for predicting human responses, reducing reliance on animal models, and improving translational outcomes. These micro engineered devices provide dynamic, functional tissue environments that support complex cellular interactions, making them ideal for disease modeling and safety profiling applications.

Technological advancements in microfluidics, biomaterials, and 3D cell culture are transforming the organ-on-chip landscape. Integrating these technologies with high-content imaging, automation platforms, and AI-driven data analytics enables more robust, reproducible, and scalable experiments. Emerging high-throughput systems, such as Emulate's AVA Emulation System, address the need for faster, cost-effective screening at preclinical stages. Multi-organ and interconnected chip platforms are also gaining traction, offering new possibilities for studying systemic drug effects and organ-organ interactions in a single, compact system.

Market demand for organ-on-chip technologies is growing across pharmaceutical companies, CROs, and academic institutions, driven by the need for cost-effective, human-relevant drug testing models. Interest in personalized systems using patient-derived cells and demand for scalable, GLP-compliant solutions are rising. With regulatory support from initiatives like the FDA Modernization Act 2.0 and ongoing innovation at the intersection of bioengineering and precision medicine, organ-on-chip platforms are becoming vital tools in advancing safer, faster drug development.

 Request a free sample copy or view report summary: U.S. Organ-on-a-Chip Market Report

U.S. Organ-on-a-Chip Market Report Highlights

• By product & service, the services segment led the market with the largest revenue share of 52.17% in 2024. This dominance is driven by the increasing demand for contract-based research, custom organ-on-chip development, assay validation, and data analysis services. The growing complexity of organ models and the need for validated regulatory-aligned testing protocols further fuel the expansion of service-based offerings in this market.

• By application, the drug discovery segment led the market with the largest revenue share of 62.82% in 2024. Organ-on-chip systems are increasingly recognized for their ability to provide more predictive data in early-stage screening, helping pharmaceutical companies reduce attrition rates and accelerate time-to-market. These devices allow detailed pharmacokinetics, pharmacodynamics, and toxicity analysis in controlled, human-relevant models, enhancing decision-making in lead optimization and candidate selection.

• By end-use, the pharmaceutical and biotechnology segment led the market with the largest revenue share of 72.65% in 2024. These companies invest in organ-on-chip technologies to improve drug development pipelines, minimize costly late-stage failures, and comply with evolving regulatory expectations for non-animal testing models.

• In June 2025, Emulate unveiled the AVA Emulation System in Boston, an advanced organ-on-a-chip platform capable of simultaneously culturing and imaging up to 96 samples. The system is designed to streamline drug development by lowering costs and reducing manual labor.

U.S. Organ-on-a-Chip Market Segmentation

Grand View Research has segmented the U.S. organ-on-a-chip market based on the product & service, application, and end-use:

U.S. Organ-on-a-Chip Product & Service Outlook (Revenue, USD Million, 2021 - 2033)

• Products

  • Instrument

  • Devices

    • Liver-on-a-Chip

    • Lung-on-a-Chip

    • Intestine-on-a-Chip

    • Kidney-on-a-Chip

    • Heart-on-a-Chip

    • Others

• Services

U.S. Organ-on-a-Chip Application Outlook (Revenue, USD Million, 2021 - 2033)

• Drug Discovery

• Toxicology Research

• Others

U.S. Organ-on-a-Chip End Use Outlook (Revenue, USD Million, 2021 - 2033)

• Academic & Research Institutes

• Pharmaceutical & Biotechnology Companies

• Others

List of Key Players in the U.S. Organ-on-a-Chip Market

• Emulate, Inc.

• MIMETAS B.V.

• Valo Health

• Quris Technologies LTD. (Nortis, Inc.)

• AxoSim

• BICO - THE BIO CONVERGENCE COMPANY

• CN Bio Innovations Ltd

• The Charles Stark Draper Laboratory, Inc.

• SynVivo, Inc.

• AlveoliX AG